0590 etro /056

Docket No. ORT-1508 0300

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

#3

Spplicants:

Fredrik KAMME and Jessica Y. ZHU

Serial No.:

10/080,795

Art Unit:

NOT ASSIGNED

Filed:

22 February 2002

Examiner:

NOT ASSIGNED

For:

METHOD FOR GENERATING AMPLIFIED RNA

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner for Patents, Washington, D.C. 20231 on

12 March 2002

(Date of Deposit)

John W. Wallen, III, Esq.

(Name of applicant/assignee, or Registered Representative)

(Signature

12 March 2002

(Date of Signature)

Assistant Commissioner for Patents Washington, D.C. 20231

INFORMATION DISCLOSURE STATEMENT


Dear Sir:

Pursuant to 37 C.F.R. §1.56 and in accordance with 37 C.F.R. §§1.97-1.98, information relating to the above-identified application is hereby disclosed. Inclusion of information in this statement is not to be construed as an admission that this information is material as that term is defined in 37 C.F.R. §1.56(b).

Applicant(s) reserve(s) the right to establish the patentability of the claimed invention over any of the information provided herewith, and/or to prove that this information may not be prior art, and/or to prove that this information may not be enabling for the teachings purportedly offered.

This statement should not be construed as a representation that a search has been made, or that information more material to the examination of the present patent application does not exist.

In accordance with §1.97(b), since this Information Disclosure Statement is being
filed either within three months of the filing date of the above-identified national
application (other than a continued prosecution application under §1.53(d)), within
three months of the date of entry into the national stage of the above identified
application as set forth in §1.491, or before the mailing date of a first Office Action
on the merits of the above-identified application, or before the mailing date of a first
Office Action after the filing of a request for continued examination under §1.114, no
additional fee is required.
In accordance with §1.129(a), this Information Disclosure Statement is being filed in
connection with [] the first or [] second After Final Submission, therefore:
Statement in Accordance with §1.97(e) (attached); or
Please charge Deposit Account No. 10-0750/ORT-1508/JWWthe fee
of \$180.00 as set forth in §1.17(p).
In accordance with §1.97(c), this Information Disclosure Statement is being filed
after the period set forth in §1.97(b) above but before the mailing date of either a
Final Action under §1.113 or a Notice of Allowance under §1.311, or an action that
otherwise closes prosecution and that it is accompanied by one of:



\bowtie	There are no listed references which are not in the English language.
	The relevance of those listed references which are not in the English language is as follows:
	Attached are copies of search report(s) from corresponding patent application(s), which are listed on the attached Submission Under MPEP 609 D.
	Attached are the following non-published pending patent applications which may be deemed relevant, which are listed on the attached Submission Under MPEP 609 D.
	Please charge any deficiency or credit any overpayment to Deposit Account No. 10

Respectfully submitted,

John W. Wallen, III, Esq. Reg. No. 35,403 Attorney for Applicants

Johnson & Johnson One Johnson & Johnson Plaza New Brunswick, New Jersey 08933-7003 (858) 784-3239

0750/ORT-1508/JWW. This form is submitted in triplicate.

DATE: 12 March 2002